ApoB, ApoA1, and Non-HDL Cholesterol: Refining Atherogenic Risk in Glaucoma Patients

This audio article is from VisualFieldTest.com (https://visualfieldtest.com) .
Read the full article here: https://visualfieldtest.com/en/apob-apoa1-and-non-hdl-cholesterol-refining-atherogenic-risk-in-glaucoma-patients
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Understanding Lipids and Atherosclerosis in Glaucoma Glaucoma is best known as a disease of high eye pressure, but researchers are increasingly aware that vascular health also plays a role. In particular, cholesterol and related blood fats (lipids) can affect the tiny arteries supplying the optic nerve. Traditional cholesterol tests report LDL–cholesterol (LDL-C) – often called “bad” cholesterol – but newer measures like apolipoprotein B (ApoB) and non–HDL cholesterol may give a fuller picture of atherosclerotic risk. Each LDL particle carries one ApoB protein, so measuring ApoB essentially counts the number of potentially harmful particles. Non–HDL cholesterol (total cholesterol minus HDL “good” cholesterol) includes all the cholesterol in LDL and other artery-clogging particles. Studies show that these markers often better reflect heart (and vessel) disease risk than LDL-C alone () (). For example, a recent expert consensus noted that “ApoB…represents the total concentration of atherogenic lipoprotein particles” and “more accurately reflects the atherogenic burden” than LDL-C (). In other words, if you have many small LDL particles, your LDL-C (how much cholesterol they carry) might look normal, but ApoB would be high – a hidden risk. Likewise, non–HDL cholesterol covers all the cholesterol in LDL, VLDL and remnant particles, which also tracks risk better. One meta-analysis found that ApoB was the strongest cardiovascular risk predictor, followed by non–HDL-C, with LDL-C the weakest () (). In practice, if a person’s LDL-C and ApoB (or non–HDL-C) diverge, doctors consider the higher value as the true risk indicator () (). For patients, this means simple tests can be used more effectively. Standard lipid panels give total cholesterol, HDL, LDL (usually calculated), and triglycerides. You can then compute non–HDL cholesterol yourself (total minus HDL) with no extra lab order. ApoB can be measured by a blood test (though it may not be included by default), and ApoB levels directly reflect how many harmful particles are circulating. In contrast, ApoA1 – the main protein on HDL (the “good cholesterol”) – indicates protective particles. (A higher ApoB/ApoA1 ratio means more “bad” particles relative to “good.”) While IOP (eye pressure) is still the main modifiable risk in glaucoma, these lipoprotein measures help detect hidden vascular risk that might affect the optic nerve. Evidence Linking Lipids to Glaucoma Several studies have found that people with glaucoma often have less-favorable cholesterol profiles. In general, glaucoma patients tend to have higher total (“all”) cholesterol and lower HDL (“good”) cholesterol relative to people without glaucoma (). For instance, a systematic review found glaucoma patients had about 8 mg/dL higher total cholesterol on average and about 2 mg/dL lower HDL (). One imaging study showed that glaucoma patients had significantly higher LDL-C and total cholesterol levels than matched controls, along with lower ocular perfusion pressure and HDL (). In that study, color Doppler blood flow scans of the eye confirmed that people with glaucoma had slower blood velocities in the retinal vessels, suggesting reduced optic nerve perfusion (). Importantly, cholesterol
Support the show (https://www.buzzsprout.com/2563091/support)

Видео ApoB, ApoA1, and Non-HDL Cholesterol: Refining Atherogenic Risk in Glaucoma Patients канала Glaucoma, Vision & Longevity: Supplements Science